Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease

Completed

Conditions studied: Gastroesophageal Reflux

In brief

This study will use a 22 gene pharmacogenomics panel on 30 children with persistent Gastroesophageal Reflux Disease (GERD) who have not responded to therapy.

Key facts

Study ID

NCT03005080

Run by

Mayo Clinic

People needed

51

Starts

2016-12-01

Expected to finish

2018-10-01

Last updated by the study team

2019-04-09

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• persistent gastrointestinal symptoms (GI) suggestive of gastro esophageal reflux disease (GERD) despite adequate therapy
• persistent evidence of abnormal reflux indices' and acid exposure on esophageal multichannel pH impedance study despite adequate therapy
• persistent endoscopic evidence of reflux esophageal disease despite adequate therapy

You may not qualify if…

• children with eosinophilic esophagitis diagnosis
• children with any esophageal surgical intervention like fundoplication, tracheoespahgeal fistula repair or esophageal atresia repair
• children with other diseases that can affect the esophagus, like Crohn's disease or food protein-induced enterocolitis syndrome (F-PIES)
• Children who do not have research authorization in their chart

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.